Antifibrotic potential of bone marrow‑derived mesenchymal stem cells in biliary atresia mice

Area of Science:

• Hepatology
• Stem Cell Therapy
• Pediatric Gastroenterology

Background:

• Biliary atresia (BA) is a severe infantile disease causing bile duct destruction, fibrosis, and potentially fatal cirrhosis.
• Fibroinflammatory processes characterize BA, leading to significant liver damage if left untreated.
• Bone marrow-derived mesenchymal stem cells (BMMSCs) are investigated for their therapeutic potential in fibrotic conditions.

Purpose of the Study:

• To evaluate the anti-fibrotic effects of BMMSC transplantation in a mouse model of biliary atresia.
• To determine if BMMSC therapy can ameliorate liver damage and fibrosis associated with BA.

Main Methods:

• A mouse model of biliary atresia was induced using Rhesus rotavirus in neonatal mice.
• Biochemical markers of liver injury (liver enzymes, bilirubin) and oxidative stress (MDA, superoxide dismutase, glutathione peroxidase) were assessed.
• Histopathological analysis using hematoxylin and eosin and Masson's trichrome staining evaluated liver fibrosis and collagen deposition.
• The impact of BMMSC transplantation on these indicators was examined.

Main Results:

• Biliary atresia model mice exhibited elevated liver enzymes, bilirubin, malondialdehyde (MDA), and fibrosis markers, with reduced antioxidant enzymes.
• Histological examination confirmed severe liver fibrosis and collagen accumulation in BA livers.
• BMMSC transplantation led to the reversal of these pathological and biochemical indicators in BA mice.

Conclusions:

• BMMSC transplantation demonstrated significant anti-fibrotic potential in a mouse model of biliary atresia.
• This study suggests BMMSCs may offer a novel therapeutic strategy for mitigating the fibrotic response in biliary atresia patients.